Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1727269 | 0.90 | HRH3 (0.42) | HRH3GRM2ADORA2AADORA2BMCHR1 | |
| SCHEMBL1727555 | 0.86 | HRH3 (0.41) | HRH3GRM2ADORA2AADORA2BACACB | |
| SCHEMBL1728684 | 0.85 | HRH3 (0.39) | HRH3ACACBALDH1A1 | |
| SCHEMBL1729503 | 0.84 | HRH3 (0.40) | HRH3GRM2ADORA2AADORA2BACACB | |
| SCHEMBL14446163 | 0.83 | HRH3 (0.40) | HRH3GRM2ADORA2AADORA2BMCHR1 | |
| SCHEMBL1728623 | 0.83 | HRH3 (0.41) | HRH3MCHR1 | |
| SCHEMBL6081381 | 0.81 | HRH3 (0.38) | HRH3MCHR1ACACBALDH1A1 | |
| SCHEMBL1728627 | 0.79 | CYP19A1 (0.42) | HRH3ADORA2AADORA2BALDH1A1 | |
| SCHEMBL14446175 | 0.79 | HRH3 (0.39) | HRH3GRM2ADORA2AADORA2BMCHR1 | |
| SCHEMBL1728518 | 0.79 | FFAR4 (0.42) | HRH3GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141561-B2 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-28 | — | — | US | disclosed |
| EP-1551810-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | Aventis Pharma Deutschland GmbH (DE) | 2005-07-13 | — | — | EP | disclosed |
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-08 | — | — | US | disclosed |
| WO-2004012648-A2 | SUBSTITUTED DIARYL HETEROCYCLES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004011438-A1 | DIARYL-SUBSTITUTED CYCLIC UREA DERIVATIVES HAVING AN MCH-MODULATORY EFFECT | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132752-A1 | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | GPR119, GLP1R, SLC5A2 | HRH3 1710/4885GRM2 337/4885ADORA2A 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.